RECCE PHARMACEUTICALS LTD — Director's Dealing 2021

Feb 24, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Recce Pharmaceuticals Ltd ( Company ) ACN 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Hamilton Bray Graham
Date of last notice	2 September 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest	N/A
(including registered holder)
Note: Provide details of the circumstances giving rise
to the relevant interest.
Date of change	22 February 2021
No. of securities held prior to	Total ordinary shares held after change: 5,984,082
change
	Direct Interest:
	1. 2,840,332 ordinary shares
	2. 389,712 Class B Performance Shares
	Indirect Interest:
	Mr. James Graham <J Graham Family A/c>
	1. 2,493,750 ordinary shares
	2. 356,250 Class B Performance Shares
	Bulleen Pty Ltd
	1. 650,000 ordinary shares
Class	Unlisted Options

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number acquired	2,250,000 Unlisted Options, each exercisable at$1.56, expiring 22 February 2026
Number disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details andestimated valuation	Nil cash consideration. Issue of Unlisted Options asapproved by shareholders at the Annual GeneralMeeting held on 30 November 2020. Further detailson the issue can be found in the Notice of Meetingreleased to ASX on 30 October 2020.
No. of securities held after change	Total ordinary shares held after change: 5,984,082Direct Interest:1. 2,840,332 ordinary shares2. 389,712 Class B Performance Shares3. 2,250,000 Unlisted OptionsIndirect Interest:Mr. James Graham <J Graham Family A/c>1. 2,493,750 ordinary shares2. 356,250 Class B Performance SharesBulleen Pty Ltd1. 650,000 ordinary shares
Nature of changeExample: on-market trade, off-market trade, exerciseof options, issue of securities under dividendreinvestment plan, participation in buy-back	Issue of Unlisted Options as approved byshareholders at the Annual General Meeting heldon 30 November 2020

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior tochangeNote: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimated valuation	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest after change	N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearance wasrequired?	No
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3